Paul G. Kluetz

9.9k total citations · 1 hit paper
174 papers, 4.0k citations indexed

About

Paul G. Kluetz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Paul G. Kluetz has authored 174 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 61 papers in Economics and Econometrics. Recurrent topics in Paul G. Kluetz's work include Health Systems, Economic Evaluations, Quality of Life (51 papers), Economic and Financial Impacts of Cancer (38 papers) and Statistical Methods in Clinical Trials (31 papers). Paul G. Kluetz is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (51 papers), Economic and Financial Impacts of Cancer (38 papers) and Statistical Methods in Clinical Trials (31 papers). Paul G. Kluetz collaborates with scholars based in United States, Netherlands and Canada. Paul G. Kluetz's co-authors include Richard Pazdur, Julia A. Beaver, Rajeshwari Sridhara, Ethan Basch, Kirsten B. Goldberg, Gideon M. Blumenthal, Sandra A. Mitchell, Marc R. Theoret, Diana T. Chingos and Laleh Amiri‐Kordestani and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Paul G. Kluetz

157 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Paul G. Kluetz

Since Specialization

Citations

This map shows the geographic impact of Paul G. Kluetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul G. Kluetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul G. Kluetz more than expected).

Fields of papers citing papers by Paul G. Kluetz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul G. Kluetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul G. Kluetz. The network helps show where Paul G. Kluetz may publish in the future.

Co-authorship network of co-authors of Paul G. Kluetz

This figure shows the co-authorship network connecting the top 25 collaborators of Paul G. Kluetz. A scholar is included among the top collaborators of Paul G. Kluetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul G. Kluetz. Paul G. Kluetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD 2025 ·Clinical Cancer Research ·Kelly J. Norsworthy, Donna R. Rivera, Joseph Wynne, Jian Zhao, (unknown), (unknown), Jonathon Vallejo, (unknown), Ólanrewaju O. Okusanya, Brian Booth, Paul G. Kluetz, Richard Pazdur, R. Angelo de Claro	0
2	Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions 2025 ·The Lancet Oncology ·Francesco Pignatti, Peter G. M. Mol, Chantal Quinten, Douwe Postmus, Anja Schiel, (unknown), (unknown), Vishal Bhatnagar, Paul G. Kluetz	0
3	Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer 2025 ·Journal of Clinical Oncology ·Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H. Fiero, Hui Zhang, Xin Gao, Matthew Neilson, Kirsten B. Goldberg, Abhilasha Nair, Tiffany K. Ricks, William F. Pierce, Nicole Gormley, Marc R. Theoret, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri‐Kordestani	1
4	The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials 2025 ·JNCI Cancer Spectrum ·Elaine Chang, Haley Gittleman, (unknown), Erik Bloomquist, (unknown), Chana Weinstock, Sundeep Agrawal, Nicole Gormley, Shenghui Tang, Daniel L. Suzman, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, David H. McDermott, Meredith M. Regan, Brian I. Rini	0
5	US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy 2024 ·Journal of Clinical Oncology ·Elizabeth S. Duke, Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera, Emily Wearne, Claudia P. Miller, John Leighton, (unknown), Hong Zhao, (unknown), Barbara Scepura, Richard Pazdur, Harpreet Singh, Paul G. Kluetz, Martha Donoghue, Nicole Drezner	5
6	Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis 2024 ·Journal of Clinical Oncology ·Jaleh Fallah, Jianjin Xu, Chana Weinstock, Xin Gao, Brian L. Heiss, William F. Maguire, Elaine Chang, Sundeep Agrawal, Shenghui Tang, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, Daniel L. Suzman	33
7	Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium 2024 ·Clinical Cancer Research ·Jason Fangusaro, Robert A. Avery, Michael J. Fisher, Roger J. Packer, Karin S. Walsh, Antoinette Y. N. Schouten‐van Meeteren, Dominik Karres, Diana Bradford, (unknown), Harpreet Singh, Paul G. Kluetz, Martha Donoghue, Elizabeth S. Duke	4
8	FDA Approval Summary: Capecitabine Labeling Update under Project Renewal 2024 ·Clinical Cancer Research ·Sundeep Agrawal, (unknown), William F. Pierce, (unknown), (unknown), Melanie Royce, Christy Osgood, Laleh Amiri‐Kordestani, Haw-Jyh Chiu, Tiffany K. Ricks, (unknown), Jeanne Fourie Zirkelbach, Rosane Charlab, Michael Pacanowski, Tamy Kim, Richard Pazdur, Paul G. Kluetz, Jennifer Gao	0
9	FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer 2024 ·Clinical Cancer Research ·Sandra J. Casak, Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng, Pallavi S. Mishra‐Kalyani, Shenghui Tang, Steven J. Lemery, (unknown), (unknown), Paul G. Kluetz, Richard Pazdur, Lola A. Fashoyin‐Aje	7
10	FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·(unknown), Gautam U. Mehta, Paz J. Vellanki, Erin Larkins, Paul G. Kluetz, Harpreet Singh	0
11	FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum 2023 ·Clinical Cancer Research ·(unknown), Diana Bradford, (unknown), Pallavi S. Mishra‐Kalyani, Yuan Li Shen, (unknown), (unknown), (unknown), (unknown), Rosane Charlab, Jeffrey Kraft, Sachia G. Khasar, Claudia P. Miller, Donna R. Rivera, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue	16
12	Evaluating Pneumonitis Incidence in Patients with Non–small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data 2023 ·Cancer Research Communications ·Qi Liu, Chenan Zhang, (unknown), (unknown), Shiew‐Mei Huang, Erin Larkins, (unknown), Donna R. Rivera, Paul G. Kluetz, Shenggang Wang, Hao Zhu, James L. Weese, (unknown), (unknown), (unknown), (unknown), (unknown)	2
13	FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer breakdown → 2022 ·Clinical Cancer Research ·Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, (unknown), Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, (unknown), Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz	127
14	The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology 2021 ·Clinical Cancer Research ·Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani, Julia A. Beaver, Lola A. Fashoyin‐Aje, Nicole Gormley, (unknown), Steven J. Lemery, Pallavi S. Mishra‐Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur	1
15	FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer 2021 ·The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh	102
16	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group 2021 ·Clinical Cancer Research ·Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, (unknown), Allen S. Melemed, Fernanda I. Arnaldez, Upal Roy, Caroline Schenkel, (unknown), Elizabeth Garrett‐Mayer	44
17	An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer 2020 ·Clinical Cancer Research ·Michael H. Brave, Chana Weinstock, Jamie R. Brewer, (unknown), Daniel L. Suzman, Joyce Cheng, Lijun Zhang, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver	20
18	FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs 2020 ·Clinical Cancer Research ·Paul G. Kluetz, Patricia Keegan, George D. Demetri, Katherine A. Thornton, Joohee Sul, (unknown), (unknown), Laurie B. Burke, R. Donald Harvey, (unknown), Sundeep Agrawal, Abhilasha Nair, Martha Donoghue, William F. Pierce, Stacy S. Shord, Jennifer Gao, Richard Pazdur	8
19	Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 2016 ·American Society of Clinical Oncology Educational Book ·Paul G. Kluetz, Diana T. Chingos, Ethan Basch, Sandra A. Mitchell	240
20	Clinical outcome assessments in neuro-oncology: a regulatory perspective 2015 ·Neuro-Oncology Practice ·Joohee Sul, Paul G. Kluetz, Elektra J. Papadopoulos, Patricia Keegan	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact